Curis Inc IND Application Cleared by the US FDA
Curis Inc (CRIS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Continue reading to learn about VISTA.
The clearance of the firm’s IND was important and considered an important . . .
This content is for paid subscribers.
Today’s Highlights June 10, 2020